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Abstract
Background
Study publication bias and outcome reporting bias have been recognised as two threats to
the validity of systematic reviews. The purpose of this research was to estimate the propor-
tion of missing participant outcome data from randomised controlled trials (RCTs) due to
lack of publication of whole studies and due to outcome data missing within study
publications.
Methods and Findings
Data were extracted from protocols of clinical research projects submitted to the research
ethics committee of the University of Freiburg (Germany) between 2000 and 2002 and
associated fully published articles. The total amount of published and unpublished outcome
data from all trial participants was calculated for each trial and the overall proportion of miss-
ing data from both unpublished and published trials computed. Full and partially reported
outcome data was also taken into consideration. The impact of funding source on missing-
ness was also considered at the trial level. From 308 parallel group trials in the study cohort,
167 were published and 141 were unpublished. Overall, 260,563 participants contributed to
a total of 2,618,116 participant outcome data across all trials. About half (47%) of the partici-
pant outcome data from the 308 trials was reported in full but at least 81% were partially
reported. Of the 19% of participant data that were missing, 4% was attributable to missing
data from published trials and 15% from unpublished trials. Commercially funded trials had
a higher probability of publication (relative risk 1.20, 95% confidence interval 0.86, 1.67; p =
0.27) but were less likely to fully report all outcomes than non-commercially funded trials
(relative risk 0.64, 95% confidence interval 0.30, 1.38; p = 0.26).
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Conclusions
Missing participant outcome data from both published and unpublished trials is frequent.
Clinical trial registration including outcome information not only identifies that clinical trials
exist but the systematic examination and monitoring of trial information within a registry can
help detect selective reporting of entire studies and of outcome data within studies and pos-
sibly prevent it.
Background
Study publication bias and within-study outcome reporting bias have been recognised as two
forms of reporting bias that can affect evidence based practice. There is strong evidence of an
association between direction of results and publication status; studies that report positive or
significant results are more likely to be published and outcomes that are statistically significant
have higher odds of being fully reported (range of odds ratios: 2.2 to 4.7) [1,2]. As a result of
these two forms of bias, systematic reviews summarising the available evidence are likely to
overestimate the effect of treatment [3,4]. Reporting bias may therefore result in inappropriate
health care decisions by policy makers, clinicians and patients, which potentially harm patients,
waste resources, and misguide future research. While there is growing empirical evidence for
the existence of these biases, little is known about the relative size of these two related problems
affecting the available research evidence. Using data taken from protocols of clinical research
projects submitted to the research ethics committee of the University of Freiburg (Germany)
and associated fully published articles, we estimate the proportion of missing participant out-
come data due to lack of publication of the study and the proportion due to missing outcome
data within a published study.
Methods
Data source
The data used in this study has previously been identified and evaluated in other publications
[5–7]. In brief, the Research Ethics Committee (REC) of the Albert-Ludwigs-University, Frei-
burg, Germany granted access to the electronic files of all study protocols (including amend-
ments) submitted between 2000 and 2002. Nearly half (408/917; 44%) of the studies approved
by the REC Freiburg within this time period were randomised controlled trials (RCTs). Of the
355 RCTs that started, the majority were multicentre trials and in 12%, the primary centre was
located in Freiburg. In this research article we consider only the 311 RCTs with parallel group
design that started. Trials that never started were excluded since there was no expectation that
the trial results would be published. Full study publications were identified through a system-
atic search of electronic literature databases and verification via contact with the trial authors.
Unpublished trials were defined to be trials where it was confirmed by trial authors that the
trial was completed or discontinued and there was no full study publication. To ensure that the
current dataset was as up-to-date as possible, the publication status of ongoing trials (at the
time of the original study [5]) was verified again in July 2015. This enabled us to classify all tri-
als as either published or unpublished.
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Data extraction
The total number of trials in the study cohort was separated into those that were published and
those that were unpublished. For published trials, the total number of participants was
extracted from the trial publication which represented the actual sample size achieved (i.e. the
total number randomised), the largest of which was taken if sample sizes differed across multi-
ple publications of the same trial. For unpublished trials, as an approximation to what was
actually collected (but not published), planned sample sizes were extracted from the trial proto-
col. The sample size was assumed to be the same for all trial outcomes. For each trial, published
or unpublished, we also extracted the total number of pre-specified outcomes listed in the trial
protocol. For published trials, we recorded the total number of published and unpublished out-
comes taken from the trial publication.
Published outcomes were categorised into ‘full’ reporting and ‘partial’ reporting. An out-
come was considered to be fully reported if sufficient information was provided such that the
outcome could be included in a potential meta-analysis of a systematic review in accordance to
the definitions provided in [8]. Partially reported outcomes were defined as those that were
inadequately reported for inclusion into a review meta-analysis (for example, an effect size was
presented with no measure of precision or exact p-value). An extended list of the different
types of partial reporting can be found in the data supplement (Web table B) of the main
ORBIT (Outcome Reporting Bias in Trials) manuscript [3]. The highest order of reporting was
taken for each outcome if multiple time-points were considered, for example, if an outcome
was partially reported at 3 and 6 months and fully reported at 12 months, then the outcomes
was considered to be fully reported. The source of funding was also extracted for each trial.
Funding source was categorised into commercially funded (typically funded by pharmaceutical
industry), non-commercially funded (typically funded by research councils, research founda-
tions, government ministries and charities) and trials where no source of funding was declared.
Trials were classified as commercially funded if they were partially funded by industry but were
categorised as non-commercially funded if a company provided the trial drugs (wholly or in
part) but had no role in the study design, data collection and analysis.
Data extraction from the original protocols and publications was undertaken in Freiburg in
which AB contributed. Using the database of extracted data, the required information for this
trial was data extracted independently by two researchers (KD and JJK). Any discrepancies
between the information extracted by the two reviewers were resolved through discussion and
in consultation with AB. Sample sizes and a summary of the outcome status’ (fully reported,
unreported and partially reported) for each individual trial can be found in the supporting
information file (S1 File).
Data analyses
Total amount of reported and missing participant outcome data (participant data
level). The total amount of participant outcome data from each trial was calculated to be the
planned trial sample size multiplied by the total number of pre-specified outcomes. For the
study cohort, we computed the total amount of participant data that was fully reported, par-
tially reported and missing from the published trials and the total amount of data that was
missing as a result of trials being unpublished. Using the computed metrics summed across all
trials and taking the total amount of outcome data across all trials as the denominator, we
report the following proportions:
• Proportion of fully published data
• Proportion of partially reported data
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• Proportion of fully and partially reported data
• Proportion of missing data from published trials
• Proportion of missing data from unpublished trials
• Proportion of missing data from all trials (published and unpublished).
Missing data from published trials may be due to within study selective reporting. In our
computations, we also considered partially reported outcome data as unpublished data. The
motivation here is that, although partially reported outcome data are published, they cannot be
included into a meta-analysis without obtaining further information (which is usually only
available from the authors), and therefore effectively resembles missing data in the systematic
review process.
Impact of funding source (trial level). The relative risk of full publication was compared
between commercially funded trials and non-commercially funded trials. For the published tri-
als, we also computed the relative risk of fully reporting all outcomes in commercially funded
trials compared to non-commercially funded trials.
Results
The study cohort contained 311 RCTs of which three were excluded as they presented no
results for the comparator group. This is a high risk of bias form of selective reporting which
has previously been documented [3], and our decision to exclude here is that our missing data
computations would mask this serious reporting problem by simply reducing the sample sizes
of these trials to what was either reported in the treatment arm or not reported in the compara-
tor arm. Of the remaining 308 trials, 167 were published (54%) and 141 (46%) were unpub-
lished. There was a tendency for published trials to specify more outcomes in their protocols
than unpublished trials (Table 1). Further, the median number of recruited participants was
higher than the number of planned participants in unpublished trials, and a higher proportion
of published trials were commercially funded (Table 1). The majority of trials (published and
unpublished) were multi-centre trials and of these multi-centre trials, most were international
trials (Table 1). The primary centre for the multi-centre trials was Freiberg for 12% of pub-
lished trials and 14% for unpublished trials.
The 308 published and unpublished trials contained data on 3407 distinct outcomes of
260,563 participants (Table 1). From the published trials 70% (1595/2253) of the outcomes
were published in full, 7% (167/2253) of the outcomes went unreported while the remainder
were partially reported. Clearly all 1154 outcomes from the unpublished studies went
unreported.
At the individual participant level, the total amount of participant outcome data was
2,618,116 (Table 2). Under a half of this data (47%) was fully reported but at least 81% were
partially reported. Four percent of the data was missing (within-study selective outcome
reporting) from published trials and 15% was missing from entirely unpublished trials.
Sixty percent (119/198) of commercially funded trials were published while 50% (20/40) of
non-commercially funded trials were published. A commercially funded trial had a 20%
increased probability of being published compared to a non-commercially funded trial
although this difference did not reach statistical significance (relative risk 1.20, 95% confidence
interval (0.86, 1.67; p = 0.27)). This wide confidence interval suggested that there was a high
level of uncertainty in this finding.
Of the published trials, nearly a fifth (23/119; 19%) of the commercially funded trials fully
reported all pre-specified outcomes compared to 30% (6/20) of the non-commercially funded
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Table 1. Outcome, participant and funding characteristics of trials that were published and unpublished.
All Published Unpublished
n = 308 (%)a n = 167 (%)a n = 141(%)a
Outcomes
Total number of outcomes: 3407 2253 1154
Median (per trial): 10 11 7
Interquartile range: 5 to 15 7 to 17 4 to 11
Trial participants
Total number of participants: 260,563 210,191 50,372
Median (per trial): 200 210 180
Interquartile range: 80 to 463 87 to 62 78 to 320
Funding
Commercial: 198 (64) 119 (71) 79 (56)
Non-commercial: 40 (13) 20 (12) 20 (14)
Not stated: 70 (23) 28 (17) 42 (30)
Collaboration
Single-centre: 65 (21) 28 (17) 37 (26)
Multi-centre: 243 (79) 139 (83) 104 (74)
Only multi-centre studiesb
International: 162 (67) 107 (77) 55 (53)
National: 80 (33) 32 (23) 48 (46)
Unclear: 1 (<1) 0 1 (1)
Primary centreb
Freiburg: 31 (13) 16 (12) 15 (14)
Other: 211 (87) 123 (88) 88 (85)
Unclear: 1 (<1) 0 1 (1)
acolumn percentages;
bdenominator is number of multi-centre studies
doi:10.1371/journal.pone.0157883.t001
Table 2. Proportion of reported andmissing participant outcome data.
1) Type of data (source) Total
amount
Participant data (published and unpublished studies) 2,618,116 [A]
Fully reported data (published studies) 1,233,291 [B]
Partially reported data (published studies) 892,892 [C]
Missing data (published studies) 91,381 [D]
Unpublished data (unpublished studies) 400,552 [E]
2) Proportions of total amount of outcome data
Fully published data 47% [B]/[A]
Partially reported data 34% [C]/[A]
Proportion of fully and partially reported data 81% [B+C]/[A]
Missing data from published studies (within-study selective outcome
reporting)
4% [D]/[A]
Missing data from unpublished studies (selective reporting of entire studies) 15% [E]/[A]
Missing data from all studies 19% [D+E]/[A]
Missing data from all studies (when partially reported was considered as
unpublished data)
53% [C+D+E]/
[A]
doi:10.1371/journal.pone.0157883.t002
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trials. Commercially funded trials were less likely to fully report all outcomes than non-com-
mercially funded trials although this difference again did not reach statistical significance with
a wide confidence interval denoting a high level of uncertainty in this finding (relative risk
0.64, 95% confidence interval (0.30, 1.38; p = 0.26)).
Discussion
Our study has shown that (81%) of participant outcome data from trials is either reported in
full or partially reported. Direct empirical evidence for the existence of study publication bias
and outcome reporting bias has been summarized previously but [1], to our knowledge, this
study is novel seeking to quantify how much outcome data is missing from trials and how
much of this missingness is attributable to lack of publication of entire studies or of outcomes
from studies for which other data has been published. Missing data from published studies
which could be associated with within-study selective outcome reporting appeared to be less of
a problem than missing data from entirely unpublished studies. Nevertheless we have shown
that the amount of missing data from both published and unpublished trials is more than half
(53%) if partially reported data is treated as unpublished. Considering partially reported data
as unpublished reflects the fact that such data cannot be included in a meta-analysis right
away. In a survey, most Cochrane review authors related that they requested additional unpub-
lished data from trialists but only about half of them obtain them [9]. Furthermore, partial
reporting has previously been associated with a high risk of outcome reporting bias [3,10]. Our
study is also likely to underestimate the impact of partial reporting, since outcomes with multi-
ple time-points were considered to be fully reported if just one time-point was reported in full.
Strengths and limitations of this study
We evaluated a large, unselected cohort of trials, the investigators confirmed whether or not
the trial was published if no trial publication was found by us, and two study authors indepen-
dently extracted and verified all the trial data. A limitation of our study is that we assumed that
the sample sizes from the published reports were the same for all trial outcomes. This assump-
tion may not always be realistic and may conflate attrition with the failure to report. However,
sample sizes for individual outcomes are not routinely reported for all trials thus our approach
could be consistently applied across all trials. All the trials included in the study were identified
from protocols submitted to a German REC and hence some of the final trial publications were
subsequently published in German language journals. It is possible that the results may there-
fore not fully represent cohorts of trials from other RECs. Previously, we identified four addi-
tional studies that covered the entire process from the publication of the study protocol to the
publication of the study outcomes that could have also been used as potential data sources for
comparison [1]. However, at the time of this original review, these datasets were unavailable
after several requests were made to the study authors and it remains unclear as to whether
these studies extracted data on sample sizes needed for inclusion into this current research.
These other studies were approved by the Canadian Institute of Health Research (Canada)
[11], the Scientific-Ethical Committees for Copenhagen and Frederiksberge (Denmark) [8],
Central Sydney Area Health Service Ethics Review Committee (Australia) [12] and Local
Research Ethics Committee (UK) [13].
Conclusions
The full publication of outcome data from clinical trials helps avoid unnecessary duplication of
research while clinical trial registration allows the relevant stakeholders identify that a clinical
trial exists. The systematic recording and monitoring of trial information within a registry goes
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some way to prevent and detect the selective publication and selective reporting of clinical
research outcomes.
The large proportion of partially reported outcome data suggests that journal editors and
reviewers need to more closely monitor and address this problem. Relevant reporting guide-
lines clearly advocate for complete reporting of outcome data and are endorsed by many jour-
nals [14]. However, routine checks of the essential items to be reported are often still not
implemented in peer review and editorial procedures. As summarized in recent systematic
reviews of non-publication and reporting biases [1] there is solid evidence confirming both
areas of problem [2]. Future studies need to explore ways how the known underreporting of
outcome data can be tackled effectively e.g. by creating incentives for complete and accurate
reporting of outcome data from clinical trials and for making raw trial data more accessible.
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